INTRODUCTION AND OBJECTIVES: Multi-parametric MRI (mpMRI) has revolutionized prostate diagnostics in improving the detection and accuracy of biopsies. mpMRI however remains a resource intensive tool and has operator dependent variability in its performance. Here we tested the value of PHI test in reducing and refining the use of mpMRI in prostate diagnostics.
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METHODS: This study represents the initial findings of the ongoing prospective UK PRIM study. 289 men referred for the first time to a prostate diagnostic clinic in our centre had a PHI assay done prior to image-targeted fusion biopsy þ systematic biopsies. mpMRI were scored using the Likert scale. Men with no mpMRI lesion had systematic biopsies. Measured parameters included PSA, PSA density (PSAd), PHI, PHI density and outcomes of interest were mpMRI positivity, and any and significant cancer detection (Grade Group 2 or more). Prostate volume was derived from the mpMRI measurements.
RESULTS: The median age was 65y (IQR 59-69), PSA 8.5ng/ ml (IQR5.6-12.4) and PHI 42 . 212/289 men (73%) were mpMRI positive. 183/289 (63%) and 126/289 (44%) had any and significant cancers detected respectively. The median PHI was 47 (IQR 34-72) and 33 (IQR 24-43) in mpMRI positive and negative men respectively and 61 ( IQR 44-81) and 34 (IQR 26-44) for significant cancers and non-significant cancers/benign lesions.
In multivariate logistic regression, PHI was an independent predictor of a positive mpMRI (OR 1. Using an initial threshold PHI of !30 as a cut-point for referrals and biopsying only men with a positive mpMRI would have saved 23% mpMRI and biopsies and missed only 7/126 significant cancers (6%).
CONCLUSIONS: Use of the PHI as an initial triage test can reduce the need for men to enter the diagnostic pathway, offering savings on imaging and biopsies yet still retaining a high level of significant cancer detection. Ongoing work will continue to evaluate its use in a larger multi-center cohort along with health economic modelling. INTRODUCTION AND OBJECTIVES: Prostate health index (PHI) was found to have higher accuracy rate to distinguish malignancy from benign disease compared with prostate specific antigen (PSA). MRI-transrectal ultrasound (TRUS) fusion prostate biopsy also gave a better result for prostate cancer diagnosis, but the correlation is not thoroughly elucidated. We aimed to study the predictive power of PHI on the result of MRI-TRUS fusion prostate biopsy.
METHODS: We initiated this prospective study from March 2017 to August 2018. Patients with PSA > 4.0 ng/ml or abnormal finding in digital rectal examination were enrolled. Those patients underwent MRI-TRUS fusion biopsy after blood samples for serum total PSA (tPSA), free PSA (fPSA) and p2PSA. Prostate health index (PHI) was calculated. Receiver operating characteristic (ROC) curve and multivariate analysis were done for all markers between cancer and non-cancer patients.
RESULTS: Total 124 patients were enrolled in this study. ROC curve revealed the area under curve of prostate volume, PSA density, tPSA, fPSA%, p2PSA% and PHI are 0.648, 0.715, 0.564, 0.653, 0.739 and 0.838. PHI gave a best result in distinguishing cancer from non-cancer patients compared with others ( Figure 1) . Besides, PHI has the highest odds ratio (Table 1) .
CONCLUSIONS: PHI not only has the best accuracy for prostate cancer detection in patient underwent systemic prostate biopsy, but also has better predictive power in MRI-TRUS fusion prostate biopsy patients.
